Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : AstraZeneca
Femme et Homme
Entre 18 ans
et 99 ans
AstraZeneca
MAJ Il y a 4 ans
Étude D419BC00001 : étude de phase 3 randomisée évaluant l’efficacité du durvalumab en monothérapie associé à du trémélimumab par rapport à une chimiothérapie standard chez des patients ayant un cancer urothélial de stade 4 non résécable. [essai clos aux inclusions]
Le carcinome urothélial est le type le plus fréquent de cancer de la vessie, il représente plus de 90 % de tous les cancers de la vessie. Il peut subvenir dans n’importe quelle partie de l’appareil ur...
Pays
France
Organes
Rein
Spécialités
Immunothérapie - Vaccinothérapie
,
Chimiothérapie
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
AstraZeneca AB
MAJ Il y a 4 ans
An Open, Multi-Centre and Long-Term Extension Study to Evaluate the Safety and Tolerability of oral Tesaglitazar therapy 1 mg in patients with Type 2 Diabetes Mellitus. (Protocol Amendment Nr.1, date 2005-04-06)
The primary objective is to monitor long-term safety and tolerability of tesaglitazar 1 mg, with or without other oral antidiabetic drugs, when administered up to 104 weeks in an extension study from ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
AstraZeneca AB
MAJ Il y a 4 ans
A Multi-centre, Double-blind, Double-Dummy, Placebo-controlled, Parallel Group, Randomised, Phase IIb Proof of Concept Study with 3 oral dose groups of AZD3480 or donepezil during 12 weeks treatment in patients with Alzheimer’s Disease Estudio en fase IIB, multicéntrico, doble ciego, controlado con placebo, de grupos paralelos y aleatorizado, de tratamiento con 3 dosis orales de AZD3480 o donepezilo durante 12 semanas en pacientes con enfermedad de Alzheimer. Prueba de concepto
To prove the concept that AZD3480 improves cognition in Alzheimer's disease patients in relation to placebo and donepezil, assessed as change from baseline on Alzheimer's Disease Assessment Scale - Co...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
AstraZeneca AB
MAJ Il y a 4 ans
Study to assess the effect of AZD3241 in Multiple System Atrophy
• To assess the safety and tolerability of AZD3241. • To determine the effect of AZD3241 on microglia activation, as measured by [11C]PBR28 binding.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
AstraZeneca AB
MAJ Il y a 4 ans
An 18-week, International, Multi-centre, Randomized, Parallel-group, Double-Blind, Active-Controlled Phase IIIb Study to Evaluate the Efficacy and Safety of Saxagliptin in combination with Metformin in Comparison with Sitagliptin in combination with Metformin in Adult Patients with Type 2 Diabetes Who Have Inadequate Glycaemic Control on Metformin Therapy alone
To compare that, after 18 weeks of oral administration of double-blind treatment, the change from baseline in HbA1c achieved with saxagliptin 5 mg per day added onto metformin is non-inferior to sitag...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme Max 99 ans
AstraZeneca AB
MAJ Il y a 4 ans
To assess the effects of AZD4901 when given in multiple doses to females with Polycystic Ovary Syndrome
To determine change from baseline of LH area under the concentration curve from time zero to 8 hours postdose [AUC(0-8)] at Day 7 in comparison to placebo.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
AstraZeneca AB
MAJ Il y a 4 ans
A 24-Week Randomized, Double-Blind, Parallel-Group, Multi-Centre, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Tesaglitazar Therapy when Administered as Monotherapy to Drug-Naïve Patients with Type 2 Diabetes
To compare the efficacy of tesaglitazar (0.5 and 1 mg) given as monotherapy for 24 weeks in improving glycaemic control in patients with type 2 diabetes with placebo as determined by the absolute chan...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
AstraZeneca AB
MAJ Il y a 4 ans
A study comparing cardiovascular effects of ticagrelor and clopidogrel in patients with Peripheral Artery Disease Badanie porównujące wpływ leczenia tikagrelorem a klopidogrelem na występowanie zdarzeń sercowo-naczyniowych u pacjentów z chorobą tętnic obwodowych
The primary objective of the study is to compare the effect of long-term treatment with ticagrelor vs. clopidogrel on the event rate of the composite of CV death, MI and ischemic stroke in patients w...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
AstraZeneca AB
MAJ Il y a 4 ans
A Randomised, Placebo-controlled, Double-blind, Parallel-group, Multicentre, Phase IIa Study to Explore the Relationship between QTcF Interval at First Dose (Loading Dose) and at Steady State after Treatment with AZD1305 Extended-release Tablets or Placebo when given to Patients with Documented AF
The primary objective of this study is to explore the relationship between QTcF at first dose (loading dose) and QTcF at steady state after treatment with AZD1305, in order to identify outliers with r...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
AstraZeneca AB
MAJ Il y a 4 ans
A Multi-centre, Double-blind, Randomised Withdrawal, Parallel-group, Placebo-controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Sustained Release (Seroquel SR®) as Monotherapy in the Maintenance Treatment of Patients with Major Depressive Disorder Following an Open-Label Stabilisation Period (Amethyst Study)
The primary objective of the study is to evaluate the efficacy of quetiapine SR compared to placebo in increasing time from randomisation to a depressed event in patients with Major Depressive Disorde...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Précédent
6
7
8
9
10
11
12
13
14
15
Suivant